What You Need to Know About Your Breast Health and Mammograms
I recently attended a women’s health summit where physicians discussed screening recommendations at different ages. It made me think: How much do we really know about our breast health beyond whether our latest mammogram was “normal”?
Your mammogram report can tell you more than whether the radiologist saw something concerning. It also includes information about your breast density and recommendations for follow-up. Together with your personal and family history, these details can help you understand the recommendations made by your healthcare team. [1][2]
Here are the key things worth understanding.
Breast screening guidelines: When should you get a mammogram?
For women at average risk, major U.S. organizations recommend starting mammography around age 40, but they differ on how often screening should take place:
These recommendations reflect different assessments of the benefits and harms of screening, including earlier cancer detection, false-positive findings, unnecessary biopsies, and overdiagnosis. They're helpful to know in case you want to question the screening schedule with your clinician. [3][2]
Some women need earlier or more intensive screening because of their family history, genetic findings, previous chest radiation, or personal breast health history. For women 75 and older, screening decisions should be individualized, as explained below. [4][3]
What happens after age 74? Your breast health still matters
Seeing a screening guideline end at age 74 can feel unsettling. You may wonder: “Does this mean I no longer need mammograms or that my health is no longer a priority?”
Neither is what the guideline means. There is no universal age at which every woman should stop breast cancer screening. Instead, recommendations differ, and the decision becomes more individualized. [3][2][5]
Why do some guidelines stop at 74?
The U.S. Preventive Services Task Force recommends mammograms every two years through age 74. For women 75 and older, it concludes that there is not enough evidence to determine the overall balance of benefits and harms. Importantly, the randomized screening trials it reviewed did not include women age 75 or older. Other evidence is mixed. This is a research gap and not a recommendation that every woman stop screening on her 75th birthday. [3]
Other organizations take a different approach:
The American Cancer Society recommends continuing screening as long as a woman is in good health and is expected to live at least another 10 years. [2]
The American College of Radiology and Society of Breast Imaging recommend continuing screening beyond age 74 unless severe coexisting illnesses limit life expectancy. [5]
What should guide the decision?
Your age is part of the discussion, but it should not be the entire discussion. You and your clinician should consider your overall health, breast cancer risk, other medical conditions, preferences, and whether you would want and be able to undergo further testing and treatment if screening found something concerning. [3][2]
Screening can find cancer earlier, but it can also lead to false alarms, biopsies, and treatment for cancers that would never have caused problems during a person’s lifetime. These tradeoffs become especially important when someone has serious health conditions that limit life expectancy. Choosing to stop screening in that situation can be thoughtful, individualized care and not abandonment. Continuing screening may also be reasonable for an older woman in good health. [3][2]
The American Cancer Society’s “10 more years” recommendation is a guide for weighing potential benefit, not an exact prediction of how long any individual will live. The conversation should focus on your health and goals, not simply the number on your birthday cake. [2]
Ask for a conversation, not an automatic cutoff
If you are told that you no longer need mammograms, it is reasonable to ask:
“I’ve had mammograms yearly up to this point. What were the deciding factors that lead to this change?
“What are the potential benefits and downsides of continuing screening for me?”
“If I stop routine screening, what changes should prompt an appointment?”
Whether you continue or stop routine screening, new breast symptoms still deserve medical evaluation. A new lump, nipple discharge, skin change, or other new breast change should not be dismissed because of your age or because routine mammograms have stopped. Evaluating a symptom is different from screening someone who has no symptoms. [2][3]
Your breast health does not stop mattering at 75. You deserve a clear explanation, a chance to ask questions, and a screening decision made with you and not simply for you.
What is the difference between 2D and 3D mammography?
A conventional 2D mammogram produces flat X-ray images of the breast. A 3D mammogram, also called digital breast tomosynthesis, creates images that allow the radiologist to examine the tissue in thin sections.
Studies suggest that 3D mammography can reduce callbacks and detect more cancers than 2D mammography. Both are accepted screening options. Ask your imaging center which it offers and whether there would be additional out-of-pocket costs. [2]
Know your breast cancer risk
The ACR recommends that all women have a breast cancer risk assessment by age 25, particularly Black women and women of Ashkenazi Jewish ancestry, to identify those who may benefit from screening before age 40. If you are older and have never discussed your risk, it is still worth asking. [4]
A risk assessment may help determine whether you need genetic counseling, additional imaging, or a discussion about risk-reduction options. Ask your clinician:
Common breast cancer risk calculators
Different models use different information and answer somewhat different questions. Their results are estimates and not predictions of whether an individual woman will develop cancer. The same woman can receive different estimates from different models. [2][7]
1. Tyrer–Cuzick, also called IBIS
Tyrer–Cuzick is commonly used to estimate ten-year and lifetime breast cancer risk and can help inform discussions about supplemental MRI screening. Depending on the version, it considers information such as:
You can review the MagView Tyrer–Cuzick calculator before a medical appointment, but have your clinician verify the inputs and interpret the result. This model is not intended for people already diagnosed with breast cancer. [6]
2. Gail model, also called the NCI Breast Cancer Risk Assessment Tool
The Gail model estimates the risk of invasive breast cancer over the next five years and through age 90. It considers factors including age, reproductive history, previous breast biopsies, and breast cancer in first-degree female relatives such as mothers, sisters, and daughters. It does not incorporate breast density or the same extended family history used in more detailed models. [7]
Because MRI eligibility based on family history should be assessed with a model that includes first- and second-degree relatives on both sides of the family, Gail is generally not the appropriate tool for that decision. The NCI also cautions that its calculator cannot accurately estimate risk in women with previous breast cancer, DCIS, or LCIS. [2][7]
3. Breast Cancer Surveillance Consortium, or BCSC
The BCSC’s current version 3 calculator estimates five-year invasive breast cancer risk. BCSC risk assessment incorporates breast density, making it another useful tool for discussing risk and prevention with a clinician. It does not provide the lifetime-risk estimate used for the common 20% MRI screening threshold. [9][10]
What does “high risk” mean?
A calculated lifetime breast cancer risk of 20% or higher is an important threshold in the ACR’s recommendations for annual supplemental MRI. The American Cancer Society uses approximately 20%–25% or greater, based on models that rely substantially on family history. [4][2]
For orientation, lifetime-risk estimates are often described as:
Estimated lifetime risk | Common description |
Below 15% | Lower or average-risk range |
15% to less than 20% | Intermediate-risk range |
20% or higher | High-risk range under ACR MRI guidance |
These ranges are not a complete screening plan. A personal history of breast cancer, a high-risk biopsy finding, genetic susceptibility, or prior chest radiation may change recommendations independently of a calculator result. [2][4]
Who may need a high-risk screening plan without relying on a calculated percentage?
Examples include women who:
Have a known BRCA1 or BRCA2 pathogenic variant.
Have a first-degree relative with a BRCA1 or BRCA2 variant but have not themselves been tested.
Received radiation therapy to the chest before age 30.
Have certain other hereditary cancer syndromes. [2]
Other genetic findings require gene-specific advice rather than assuming that every mutation carries the same risk or screening recommendation. [4][2]
Women with atypical hyperplasia or lobular carcinoma in situ, known as LCIS, also need individualized risk assessment. These findings should not automatically be assigned to one lifetime-risk category. [2]
Understanding your mammogram report
Radiologists use the Breast Imaging Reporting and Data System, or BI-RADS, to describe imaging findings and recommended next steps. The numerical assessment runs from 0 through 6. [1]
BI-RADS category | What it means | Typical next step |
0 | Incomplete | Additional imaging and/or comparison with earlier studies |
1 | Negative | Continue screening on the recommended schedule |
2 | Benign finding | Continue screening on the recommended schedule |
3 | Probably benign | Short-interval imaging follow-up, often beginning around six months |
4 | Suspicious abnormality | Biopsy is generally recommended |
5 | Highly suggestive of malignancy | Biopsy is strongly recommended |
6 | Cancer already confirmed by biopsy | Imaging may help guide treatment or assess response |
A category 0 result does not mean cancer was found. It means the radiologist needs more information before giving a final assessment. A category 3 finding has no more than a 2% likelihood of being cancer, which is why follow-up imaging is often recommended rather than an immediate biopsy. [1]
A screening result is not the same as a diagnosis. When imaging shows a suspicious finding, a biopsy is usually needed to determine whether it is cancer. [1]
Breast density: A separate part of your report
Since September 10, 2024, mammography facilities subject to federal mammography quality standards must notify patients whether their breasts are dense or not dense. The report sent to the healthcare provider includes one of four density categories. [11]
Density category | Description | Considered dense? |
A | Almost entirely fatty | No |
B | Scattered areas of fibroglandular tissue | No |
C | Heterogeneously dense | Yes |
D | Extremely dense | Yes |
Density categories describe tissue composition, not whether cancer is present. They are separate from the numerical BI-RADS assessment of imaging findings. You can have dense breasts and a negative mammogram. [11][1]
Dense tissue matters for two reasons:
It can make cancers harder to see on a mammogram.
It is independently associated with a higher risk of developing breast cancer. [11]
Having dense breasts does not mean you have cancer, and it does not automatically mean you need a biopsy.
Do dense breasts mean you need ultrasound or MRI?
Not necessarily. The decision depends on your density, overall risk, medical history, preferences, and the benefits and potential downsides of additional testing. Major guidelines differ. [12][3]
What the ACR says
The ACR’s supplemental screening criteria make these distinctions:
Situation | ACR assessment of supplemental imaging |
Average risk with category C, heterogeneously dense breasts | MRI, abbreviated MRI, or ultrasound may be appropriate |
Average risk with category D, extremely dense breasts | MRI or abbreviated MRI is usually appropriate; ultrasound may be appropriate |
Intermediate risk with dense breasts | MRI or abbreviated MRI is usually appropriate |
High risk, regardless of density | MRI or abbreviated MRI is usually appropriate |
“May be appropriate” does not mean everyone in that group needs the test. It means the test can be reasonable in the specified circumstances and should be considered individually. [12]
The ACR also recommends annual supplemental breast MRI for women diagnosed with breast cancer before age 50, or women with a personal history of breast cancer who also have dense breasts. [4]
What the USPSTF says
The USPSTF finds insufficient evidence to recommend for or against supplemental ultrasound or MRI solely because a woman has dense breasts and an otherwise negative mammogram. This is not a recommendation against additional imaging; it means the available evidence does not establish the overall balance of benefits and harms well enough for a population-wide recommendation. [3]
How do the tests differ?
Breast MRI is highly sensitive and can find cancers missed on mammography. Standard screening MRI uses intravenous contrast and can also lead to additional imaging or biopsies for findings that turn out to be benign. When indicated, MRI generally supplements rather than replaces mammography. [2][3]
Breast ultrasound uses no ionizing radiation or intravenous contrast. It can detect additional cancers, but MRI generally detects more; ultrasound can also produce false-positive findings and unnecessary biopsies. [12]
Ask about the full cost and insurance coverage before scheduling supplemental imaging. Coverage should not be assumed simply because a test is recommended.
A callback is different from supplemental screening
These are two different situations:
A diagnostic callback occurs when the screening examination is incomplete or shows something that needs clarification. The next step may be additional mammogram views, comparison with older images, ultrasound, or if a finding remains suspicious, a biopsy. [1]
Supplemental screening may be considered after an otherwise negative mammogram because of high risk, dense breasts, or another qualifying factor. Dense tissue alone is not a suspicious mass or a reason to proceed directly to biopsy. [12][11]
Your mammogram report, family history and risk estimate are most useful when you look at them together. This is the kind of preparation I help clients with in coaching: organizing their history, completing a risk calculator such as Tyrer–Cuzick ahead of time, understanding what their report says, and arriving at their appointment with focused questions. Decisions about screening and imaging stay with you and your physician. My role is to help you walk into that conversation prepared.
This article provides general education with supporting references, and does not replace individualized medical advice.
References
1. American Cancer Society. Understanding Your Mammogram Report. View source
2. American Cancer Society. American Cancer Society Recommendations for the Early Detection of Breast Cancer. View source
3. U.S. Preventive Services Task Force. Breast Cancer: Screening. April 30, 2024. View source
4. American College of Radiology. New ACR Breast Cancer Screening Guidelines Call for Earlier Screening for High-Risk Women. May 3, 2023. View source
5. American College of Radiology and Society of Breast Imaging. ACR/SBI Statement on New USPSTF Breast Cancer Screening Recommendations. May 9, 2023. View source
6. MagView. Tyrer-Cuzick Risk Assessment Calculator. View source
7. National Cancer Institute. Breast Cancer Risk Assessment Calculator. View source
8. Performance of the Tyrer-Cuzick 8 Breast Cancer Risk Model Across a Spectrum of Breast Densities. 2022. View source
9. Breast Cancer Surveillance Consortium. Tools. View source
10. Breast Cancer Surveillance Consortium. Archived Press Announcements, 2004–2018. View source
11. U.S. Food and Drug Administration. Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA). View source
12. American College of Radiology. ACR Appropriateness Criteria: Supplemental Breast Cancer Screening Based on Breast Density. View source
Comments